Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319717 | 0.82 | TSHR (0.42) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3905072 | 0.80 | PPARD (0.39) | TSHRTP53TDP1PPARDKDM4E | |
| SCHEMBL8199890 | 0.80 | GAA (0.44) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1879478 | 0.80 | TSHR (0.39) | POLBTSHRTP53TDP1PPARD | |
| SCHEMBL5839781 | 0.80 | GAA (0.40) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10108 | 0.80 | GAA (0.40) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9445952 | 0.80 | GAA (0.40) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9445956 | 0.80 | POLB (0.43) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL31267383 | 0.79 | GAA (0.36) | POLBGAACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17937995 | 0.79 | POLB (0.46) | POLBGAACYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882030-B1 | NON-AQUEOUS ELECTROLYTE AND ENERGY STORAGE DEVICE USING THE SAME | UBE INDUSTRIES (JP) | 2017-06-21 | — | — | EP | claimed |
| CN-103819484-B | Synthesis method for natural jolkinolide A and B | 中国药科大学 | 2017-04-19 | — | — | CN | claimed |
| CN-103819484-A | Synthesis method for natural jolkinolide A and B | UNIV CHINA PHARMA | 2014-05-28 | — | — | CN | claimed |
| CN-102653543-A | Preparation method, biological activity and application of 3-substituted type Jolkinolide compound | UNIV CHINA PHARMA | 2012-09-05 | — | — | CN | claimed |
| CN-102558288-A | Preparation method of jolkinolide compound and application thereof | UNIV CHINA PHARMA | 2012-07-11 | — | — | CN | claimed |
| EP-1554330-B1 | PARTIALLY ESTER-EXCHANGED SIPM AND PROCESS THEREWITH | INVISTA TECH SARL (CH) | 2009-03-11 | — | — | EP | claimed |
| EP-1615934-B1 | TITANIUM CHELATE DISPERSIONS | DU PONT (US) | 2007-06-27 | — | — | EP | claimed |
| EP-1001951-B1 | THIAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE | SCHERING AG (DE) | 2002-09-25 | — | — | EP | claimed |
| JP-2000500758-A | — | — | 2000-01-25 | — | — | JP | claimed |
| EP-0862575-A1 | NOVEL GERANYLGERANYL-DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND RELATED PHARMACEUTICAL COMPOSITIONS | LABORATORI BALDACCI Spa (IT) | 1998-09-09 | — | — | EP | claimed |
| WO-1997019091-A1 | NOVEL GERANYLGERANYL-DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND RELATED PHARMACEUTICAL COMPOSITIONS | LABORATORI BALDACCI S.P.A. (IT) | 1997-05-29 | — | — | WO | claimed |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4634167-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250270224-A1 | POLYCYCLIC POLY(ADP-RIBOSE) POLYMERASE SELECTIVE INHIBITOR | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2025-08-28 | — | — | US | disclosed |
| CN-120092010-A | Polycyclic poly (ADP-ribose) polymerase selective inhibitors | 轩竹生物科技股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-4307232-A | Preparation of dialkyl- and diarylphosphonoalkanoic acids and substituted acrylic acids | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-12-22 | — | — | US | disclosed |
| US-4265769-A | CORROSION RESISTANCE, ANTISCALING AGENTS | CIBA-GEIGY CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| US-4208344-A | CORROSION RESISTANCE, ANTISCALING AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
| US-3935271-A | INSECTICIDE | SANDOZ LTD. (CH) | 1976-01-27 | — | — | US | disclosed |
| US-3932483-A | INSECTICIDES | SANDOZ LTD., (SANDOZ AG) (CH) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270224-A1 | POLYCYCLIC POLY(ADP-RIBOSE) POLYMERASE SELECTIVE INHIBITOR | PARP1, PARP11, PARP2 | POLB 31/4885GAA 274/4885CYP3A4 1409/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | POLB 3837/4885GAA 791/4885CYP3A4 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.